Reminder – NCI SBIR Contracts Funding Webinar

Wednesday, October 30, 2013, 3:00 p.m. – 4:30 p.m. EDT
Register Today: http://bit.ly/NCIsbir1030

Learn about current high priority funding areas of the National Cancer Institute Small Business Innovation Research (NCI SBIR) Program in the SBIR Contract Solicitation PHS 2014-1 due November 25 by 4:30 p.m. EDT (please note that the due date has been extended). For additional information about the extended deadline and amendments to this solicitation, please see the NIH Guide Notice (NOT-OD-14-013). Contract funding opportunities are only available once a year, so don’t miss your chance.Attend the NCI SBIR Contracts Funding Webinar on Wednesday, October 30 to hear about the NCI SBIR Program and this year’s contract opportunities worth over $5M. The NCI SBIR Development Center funds 300 – 400 early-stage cancer technology projects with an annual budget of over $100M.

NCI SBIR Contracts Funding Webinar

October 30, 2013
3:00 pm – 4:30 pm (EDT)This event will include:

  • Overview of the NIH/NCI SBIR & STTR Programs
  • Description of the SBIR contracts funding process
  • Details on NCI’s FY14 high priority contract funding opportunities (Visit http://sbir.cancer.gov/funding/contracts/ and see below)
  • Open Q&A session

Registration is free but required. To register, please click here.

Please feel free to share this webinar invitation with anyone else you believe may be interested.

The FY2014 NIH and CDC SBIR contract solicitation (PHS-2014-1) provides funding opportunities to small businesses to support research, development, and commercialization in the following areas of priority to the NCI:

Cancer Therapy and Diagnosis 

  • Topic 326 Development of Novel Therapeutic Agents that Target Cancer Stem Cells
  • Topic 327 Reformulation of Failed Chemotherapeutic Drugs
  • Topic 331 Development of a Biosensor-Based Core Needle Tumor Biopsy Device
  • Topic 332 Development of Radiation Modulators for Use During Radiotherapy

Advancing Cancer Research

  • Topic 328 Validation of 3D Human Tissue Culture Systems that Mimic the Tumor Microenvironment
  • Topic 329 Proteomic Analysis of Single Cells Isolated from Solid Tumors
  • Topic 330 Generation of Site-Specific Phospho-Threonine Protein Standards for use in Cancer Assays

Health IT

  • Topic 333 Software Tools for the Development of Environmental Measures Related to Cancer Health Behaviors and Resources

If you have questions about any of the topics or general questions on contract administration, please contact: Ms. Elizabeth Shanahan at eshanahan@mail.nih.gov or (240) 276-5432. Please reference solicitation PHS 2014-1 and the Topic number with any questions.

Learn more about the difference between SBIR contracts and grants by clicking here.

There are many benefits to applying for NCI SBIR & STTR funding opportunities, such as:

  • SBIR & STTR funding can be a leveraging tool to help attract additional funding from other third-party investors.
  • Awards are not loans; no repayment is required.
  • SBIR & STTR funding is non-dilutive capital (i.e., an award does not impact the company’s stock or shares in any way). Intellectual property rights to technologies developed under these programs are retained by the small business concern.
  • SBIR & STTR awards provide recognition, verification, and visibility.

Additional Funding Opportunities
NCI SBIR & STTR Programs funding is available through a number of contracts, grants, the Omnibus Solicitation, SBIR Phase IIB Bridge Award, and the Innovative Molecular Analysis Technologies Program. For a complete listing of all current funding opportunities available from the NCI SBIR & STTR Programs, please visit: http://sbir.cancer.gov/funding/receipt_dates.asp.

The SBIR & STTR Programs are NCI’s engine of innovation for developing and commercializing novel technologies and products to prevent, diagnose, and treat cancer. The SBIR & STTR Programs are government set-aside programs for domestic small businesses to engage in research and development that has the potential for commercialization and public benefit.